Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2004-08-20
2010-06-01
Johannsen, Diana B (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C435S091500, C435S091510, C536S023500
Reexamination Certificate
active
07727714
ABSTRACT:
The present invention provides a method for inhibiting growth of a cancer cell, particularly a renal cell carcinoma, by contacting the cell with a composition composed of an HIG2 siRNA or HIG2 antibody. Methods of diagnosing renal cell cancer are also provided within the present invention.
REFERENCES:
patent: WO 01/23426 (2001-04-01), None
patent: WO 02/079411 (2002-10-01), None
patent: WO 03/032813 (2003-04-01), None
patent: WO 2008/102557 (2008-08-01), None
patent: WO 2008128043 (2008-10-01), None
Wiesener, M.S. et al. Cancer Research 61:5215-5222 (Jul. 2001).
Zhang, et al., “Foreign Medical Sciences (section of Clinical Biochemistry and Laboratory Medicine),” 2003, vol. 24(4): pp. 199-200.
Denko, Nicholas, et al.; “Epigenetic Regulation of Gene Expression in Cervical Cancer Cells by the Tumor Microenvironment;”Clinical Cancer Research; Feb. 2000; pp. 480-487; 6:2.
Togashi, A., et al.; “Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy;”The Journal of Urology; Apr. 2006; p. 1272; 175:4.
Boer, Judith M. et al., “Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array”;Genome Research11:1861-1870 (2001).
Huber, W. et al.; “Five outstanding research communications 2002”;Verh. Dtsch. Ges. Path. 86:153-164 (2002).
Jiang, Yide et al.; “Gene expression profiling in a renal cell carcinoma cell line: Dissecting VHL and hypoxia-dependent pathways”;Molecular Cancer Research1:453-462 (Apr. 2003).
Moch, H. et al.; “Identification of potential prognostic parameters for renal cell carcinoma by tissue microarray analysis and cDNA microarray screening”;Verh. Dtsch. Ges. Path. 83:225-232 (1999).
Nishie, Akihiro et al.; “High expression of theCap43gene in infiltrating macrophages of human renal cell carcinomas”;Clinical Cancer Research7:2145-2151 (Jul. 2001).
Oudard, Stephane et al.; “Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome”;Anticancer Research22:121-128 (2002).
Petros, John A. et al.; “cDNA microarray gene expression profiles of papillary renal cell carcinoma”;Journal of Urology167(4 Suppl):126-127 (505) (2002) andAnnual Meeting of the American Urology Association, Inc.; Orlando, Florida, May 25-30, 2002.
Shiina, Hiroaki et al.; “The humanT-cell factor-4gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma”;Clinical Cancer Research9:2121-2132 (Jun. 2003).
Skubitz, Keith M. and Amy P. N. Skubitz; “Differential gene expression in renal-cell cancer”;J. Lab. Clin. Med. 140:52-64 (2002).
Stassar, M.J.J.G. et al.; “Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization”;British Journal of Cancer85(9):1372-1382 (2001).
Takahashi, Masayuki et al.; “Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification”;PNAS98(17):9754-9759 (Aug. 14, 2001).
Jiang, Y., et al., “Gene Expression Profiling in a Renal Cell Carcinoma Cell Line: Dissecting VHL and Hypoxia-Dependent Pathways,”Molecular Cancer Research, vol. 1(6), pp. 453-462 (Apr. 2003).
Latif, F., et al., “Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene,”Science, vol. 260(5112), pp. 1317-1320 (May 28, 1993).
Togashi, A., et al., “Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy,”Cancer Res., vol. 65(11), pp. 4817-4826 (Jun. 1, 2005).
Togashi, A., et al., “Screening for novel therapeutic target and tumor marker of renal cell carcinoma using cDNA microarray,”Proceedings of the 62ndAnnual Meeting of the Japanese Cancer Association, p. 216, Abstract No. 3002-OA (Aug. 25, 2003).
Togashi, A., et al., “Identification of novel therapeutic target and tumor marker for renal cell carcinoma,”Proceedings of the 63rdAnnual Meeting of the Japanese Cancer Association, 95 (Supplement), p. 215, Abstract No. W-174 (Aug. 25, 2004).
Togashi, et al., “A novel potential molecular target for treatment of renal cell carcinoma (RCC),”Proceedinqs of the 95thAnnual Meeting of the American Association for Cancer Research, vol. 45, pp. 481-482, Abstract No. 2093 (Mar. 2004).
Katagiri Toyomasa
Nakamura Yusuke
Johannsen Diana B
Oncotherapy Science, Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Hypoxia-inducible protein 2 (HIG2), a diagnostic marker for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hypoxia-inducible protein 2 (HIG2), a diagnostic marker for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hypoxia-inducible protein 2 (HIG2), a diagnostic marker for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4241086